Moderna Surprises with Q3 Profit Boosted by COVID Vaccine Sales
Originally Published 1 year ago — by Moderna Investor Relations
Moderna reported third-quarter 2024 revenues of $1.9 billion, with a net income of $13 million, driven by strong sales of its updated COVID-19 vaccine. The company initiated Phase 3 trials for norovirus and influenza vaccines and expanded its executive committee. Despite a decrease in cash reserves, Moderna remains focused on achieving $3.0 to $3.5 billion in product sales for 2024 and plans to deliver 10 product approvals over the next three years. The company also announced strategic expansions and partnerships to enhance its vaccine portfolio and operational capabilities.